ERBB2 and breast carcinoma: Their findings demonstrated that AEBR significantly reduced the viability of various breast cancer cell lines, including MCF-7 (ER+, HER2/neu−), MDA-MB-231 (ER−, HER2/neu−), and MDA-MB-453 (ER−, HER2/neu+).